Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: A consensus statement using a meta-analytic approach

Annals of the Rheumatic Diseases

Volumn 63, Issue 7, 2004, Pages 759-766

  Richy, F ^a,b,c   Bruyere, O ^b,c   Ethgen, O ^b,c   Rabenda, V ^b,c   Bouvenot, G ^d   Audran, M ^e   Herrero Beaumont, G ^f   Moore, A ^g   Eliakim, R ^h   Haim, M ⁱ   Reginster, J Y ^b,c  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c WHO Collaborating Ctr Pub Hlth A   (Belgium)

^d HÔPITAL SAINTE MARGUERITE   (France)

^e ANGERS UNIVERSITY HOSPITAL   (France)

^f Department of Rheumatology ^*  (Spain)

^g Pain Research   (United Kingdom)

^h RAMBAM MEDICAL CENTER   (Israel)

ⁱ Dohme Chibret Centre de Recherche Riom   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; ETODOLAC; IBUPROFEN; INDOLE DERIVATIVE; INDOMETACIN; MELOXICAM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PIROXICAM; TENIDAP; TENOXICAM; XIMOPROFEN;

COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG USE; GASTROINTESTINAL DISEASE; HUMAN; INFORMATION RETRIEVAL; MAJOR CLINICAL STUDY; MEDICAL DOCUMENTATION; MEDICAL RESEARCH; PATIENT SELECTION; PRIORITY JOURNAL; PUBLICATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TECHNIQUE;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; GASTROINTESTINAL DISEASES; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; REGRESSION ANALYSIS; RISK ASSESSMENT;

EID: 3042701257     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.015925     Document Type: Review

References (84)

1. Garner A. Adaptation in the pharmaceutical industry, with particular reference to gastrointestinal drugs and diseases. Scand J Gastroenterol Suppl 1992;193:83-9.
2. Lichtenstein DR, Syngal S, Wolfe MM. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. The double-edged sword. Arthritis Rheum 1995;38:5-18.
3. Cash JM, Klippel JH. Second-line drug therapy for rheumatoid arthritis. N Engl J Med 1994;330:1368-75.
4. Davies NM, Wallace JL. Nonsteroidal anti-inflammatory drug-induced gastrointestinal toxicity: new insights into an old problem. J Gastroenterol 1997;32:127-33.
5. Henry D, Lim LLY, Rodriguez LAG, Gutthann SP, Carson JL, Griffin M, et al. Variability in risk of gastrointestinal complications with individual nonsteroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996;312:1563-6.
6. Tramer MR, Moore RA, Reynolds DJ, McQuay HJ. Quantitative estimation of rare adverse events which follow a biological progressions new model applied to chronic NSAID use. Pain 2000;85:169-82.
7. Hawkey CJ. NSAIDs toxicity: where are we and how do we go forward? J Rheumatol 2002;29:650-1.
8. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999;26(suppl):18-24.
9. Bollini P, Rodriguez LA, Gutthann SP, Walker AM. The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease. Arch Intern Med 1992;152:1289-95.
10. Gabriel SE, Jaakkimainen L, Bombardier C. Risk of serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A metaanalysis. Ann Intern Med 1991;115:787-95.
11. Henry D, Lim LL, Rodriguez LA, Gutthann SP, Carson JL, Griffin, et al. Variability in risk of gastrointestinal complications with individual nonsteroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996;312:1563-6.
12. Huang JG, Sridhar S, Hunt R. Role of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002;359:14-22.
13. Mamdani M, Rochon PA, Juurlink DN, Kopp A, Anderson GM, Naglie G, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional nonsteroidal anti-inflammatory drugs. BMJ 2002;325:624-7.
14. Dickersin K, Scherer R, Lefebvre C. Identifying the relevant studies for systematic reviews. BMJ 1994;309:1286-91.
15. Jadad AR, Moore RA, Carroll D, Jenkinson C. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
16. Richy F, Bousquet J, Devogelaer JP, Ehrlich G, Meunier P, Peel N, et al on behalf of the WHO Collaborating Center for Public Health Aspects of Osteoarticular Disorders, Liège, Belgium. Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporos Int 2003;14:179-90.
17. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
18. Gebuhr P, Soelberg M, Orsnes T, Wilbek H. Naproxen prevention of heterotopic ossification after hip arthroplasty. Acta Orthop Scand 1991;62:226-9.
19. Laerum E, Ommundsen OE, Christiansen A, Fagertun HE. Oral diclofenac in the prophylactic treatment of recurrent renal colic. Eur Urol 1995;28:108-11.
20. Kjaersgaard-Andersen P, Nafei A, Teichert G, Schmidt S, Keller J, Lucht U. Indomethacin for prevention of heterotopic ossification. A randomized controlled study in 41 hip arthroplasties. Acta Orthop Scand 1993;64:639-42.
21. Lemmel EM, Bolten W, Burgos-Vargas R, Platt P, Nissila M, Sahlberg D, et al. Efficacy and safety of meloxicam in patients with rheumatoid arthritis. J Rheumatol 1997;24:282-90.
22. Hoikka V, Lindholm T, Eskola A. Flurbiprofen inhibits heterotopic bone formation in total hip arthroplasty. Arch Orthop Trauma Surg 1990;109:224-6.
23. Gebuhr P, Sletgard J, Dalsgard J, Soelberg M, Keisu K, Hanninen A, et al. Heterotopic ossification after hip arthroplasty: a randomised double-blind multicenter tenoxicam in 147 hips. Acta Orthop Scand 1996;67:29-32.
24. Prupas HM, Loose LD, Spindler JS, Dietz AJ, Gum OB, Weisman MH. Tenidap in patients with theumatoid arthritis. Scand J Rheumatol 1996;25:345-51.
25. Wahlstrom O, Risto O, Djerf K, Hammerby S. Heterotopic bone formation prevented by diclofenac. Prospective study of 100 hip arthroplasties. Acta Orthop Scand 1991;62:419-21.
26. Schmidt S, Kjaersgaard-Andersen P, Pedersen N, Kristensen S, Perdersen P, Nielsen J. The use of indomethacin to prevent the formation of heterotopic bone after total hip replacement. A randomized, double-blind clinical trial. J Bone Joint Surg Am 1988;70:834-8.
27. Reis H, Kusswetter W, Schellinger T. The suppression of heterotopic ossification after total hip arthroplasty. Int Orthop 1992;16:140-5.
28. Burssens A, Thiery J, Kohl P, Molderez A, Haazen L. Prevention of heterotopic ossification with tenoxicam following total hip arthroplasty: a double-blind, placebo-controlled dose-finding study. Acta Orthop Belg 1995;61:205-11.
29. Simon LS, Weaver AL, Kivitz AJ, Lipsky PE, Hubbard RC, Isakson PC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. JAMA 1999;24:1921-8.
30. Elmstedt E, Lindholm T, Nilsson O, Tornkvist H. Effect of ibuprofen on heterotopic ossification after hip replacement. Acta Orthop Scand 1985;56:25-7.
31. Bono RF, Finkel S, Goodman HF, Hanna CB, Rabinowitz SR, Sharon E. Oxaprozin in the treatment of patients with tendonitis and bursitis: a comparison with phenylbutasone and placebo. Semin Arthritis Rheum 1986;15:90-4.
32. Withdrawn.
33. Lipscomb GR, Wallis N, Armstrong G, Rees WD. Gastrointestinal tolerability or meloxicam and piroxicam: a double-blind placebo-controlled study. Br J Pharmacol 1998;46:133-7.
34. Schnitzer TJ, Ballard IM, Constantine G, McDonald P. Double-blind, placebo-controlled comparison and efficacy of orally administrated etodolac and nabumetone in patients with osteoarthritis of the knee. Clin Ther 1995;17:602-12.
35. Patoia L, Santucci L, Furno P, Dionisi MS, Dell'Orso S, Romagnolli M, et al. A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers. Br J Rheumatol 1996;35:61-7.
36. Lund B, Distel M, Bluhmki E. A double-blind, randomized, placebo-controlled study of efficacy and tolerance of meloxicam treatment in patients with osteoarthritis of the knee. Scand J Rheumatol 1998;27:32-7.
37. Laurent J, Belghiti D, Bruneau C, Lagrue G. Diclofenac, a nonsteroidal anti-inflammatory drug, decreases proteinuria in some glomerular diseases: a controlled study. Am J Nephrol 1987;7:198-202.
38. Berry H, Bird HA, Black C, Freeman AM, Golding DN, Hamilton EB, et al. A double-blind, multicentre, placebo-controlled trial of lornoxicam in patients with osteoarthritis of the hip and knee. Ann Rheum Dis 1992;51:238-42.
39. Dougados M, Nguyen M, Caporal R, Legeais J, Bouxin-Sauzet A, Pellegri-Guegnault B, et al. Ximoprofen in ankylosing spandylitis. Scand J Rheumatol 1994;23:243-8.
40. Laine L, Sloane R, Ferretti M, Cominelli F. A randomized, double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production. Gastrointest Enclosc 1995;42:428-33.
41. Persson PE, Sodemann B, Nilsson OS. Preventive effects of ibuprofen on periarticular heterotopic ossification after total hip arthroplasty. Acta Orthop Scand 1998;69:111-15.
42. Scott DL, Berry H, Capell H, Coppock J, Daymond T, Doyle DV, et al. The long-term effects of non-steroidal anti-inflammatory drugs in osteoarthritis of the knee: a randomized placebo-controlled trial. Rheumatology (Oxford) 2000;39:1095-101.
43. Bassotti G, Bucaneve G, Fumo P, Morelli A, Del Favero A. Double-blind, placebo-controlled study of diclofenac sodium and indomethacin on postprandial gastric motility on man. Dig Dis Sci 1998;43:1172-6.
44. Dougados M, Gueguen A, Nakache JP, Velicitat P, Veys EM, Zeidler H, et al. Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology (Oxford) 1999;38:235-44.
45. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-33.
46. Yocum D, Fleischmann R, Dalgin P, Caldwell J, Hall D, Roszko P. Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, placebo-controlled trial. The meloxicam osteoarthritis investigators. Arch Intern Med 2000;160:2947-54.
47. Eliakim R, Ophir M, Rachmilewitz D. Duodenal muscosal injury with nonsteroidal antiinflammatory drugs. J Clin Gastroenterol 1987;9:395-9.
48. Doyle G, Furey E, Berlin R, Cooper S, Jayawardena S, Ashraf E, et al. Gastrointestinal safety and tolerance of ibuprofen at maximum over-the-counter dose. Aliment Pharmacol Ther 1999;13:897-906.
49. Schiff MH. A comparison of naprelan and naprosyn in the treatment of osteoarthritis of the knee. Am J Orthop 1996;25(suppl):14-20.
50. Szpalski M, Hayez JP, Objective functional assessement of the efficacy of tenoxicam in the treatment of acute low back pain. A double-blind placebo-controlled study. Br J Rheumatol 1994;33:74-8.
51. Guess HA, West R, Strand LM, Helston D, Lydick EG, Bergman U, et al. Fatal upper gastrointestinal hemorrhage or perforation among users and nonusers or nonsteroidal anti-inflammatory drugs in Saskatchewan, Canada 1983. J Clin Epidemiol 1988;41:35-45.
52. Bloom BS. Risk and cost of gastrointestinal side effects associated with nonsteroidal anti-inflammatory drugs. Arch Intern Med 1989;149:1019-22.
53. Carson JL, Strom BL, Soper KA, West SL, Morse ML. The association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding. Arch Intern Med 1987;147:85-8.
54. Withdrawn.
55. Beardon PH, Brown SV, McDevitt DG. Gastrointestinal events in patients prescribed non-steroidal anti-inflammatory drugs: a controlled study using record linkage in Tayside. Q J Med 1989;71:497-505.
56. Allison MC, Howatson AG, Torrance G, Lee FD, Russell RI. Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. N Engl J Med 1992;327:749-54.
57. MacDonald TM, Morant SV, Robinson GC, Shield MJ, McGilchrist MM, Murray FE. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 1997;315:1333-7.
58. Fries JF, Williams CA, Bloch DA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991;91:213-22.
59. Kurata JH, Nogawa AN, Novitake D. NSAIDs increase risk of gastrointestinal bleeding in primary care patients with dyspepsia. J Fam Pract 1997;45:227-35.
60. McMahon AD, Evans JM, White G, Murray FE, McGilchrist MM, McDevitt DG, et al. A cohort study (with re-sampled comparator groups) to measure the association between new NSAID prescribing and upper gastrointestinal hemorrhage and perforation. J Clin Epidemiol 1997;50:351-6.
61. Smalley WE, Ray WA, Daugherty JR, Griffin MR. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol 1995;141:539-45.
62. Garcia Sodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal bleeding associated with ketoralac, other NSAIDs, calcium antagonists and other antihypertensive drugs. Arch Intern Med 1998;158:33-9.
63. Beard K, Walker AM, Perera DR, Jick H. Nonsteroidal anti-inflammatory drugs and hospitalization for gastroesophageal bleeding in the elderly. Arch Intern Med 1987;147:1621-3.
64. Flower RJ. Non-steroidal anti-inflammatory drugs: back to the future. Rheumatology (Oxford) 1999;38:693-6.
65. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998;105(suppl):31-8s.
66. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:341-8.
67. Ofman JJ, Maclean CH, Straus WL, Morton SC, Berger ML, Roth EA, et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal anti-inflammatory drugs. J Rheumatol 2002;29:804-12.
68. Watson MC, Brookes ST, Kirwan JR, Faulkner A. Non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the knee. Cochrane Database of Systematic Reviews 2000:CD000142.
69. Henry D, Lim LL, Rodriguez LA, Gutthann SP, Carson JL, Griffin M, et al. Variability in risk of gastrointestinal complications with individual drugs: results of a collaborative meta-analysis. BMJ 1996;312:1563-6.
70. Kurato JH, Nogawa AN. Meta-analysis of risk factors for peptic ulcer. J Clin Gastroenterol 1997;24:2-17.
71. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000;321:1183-7.
72. Neal BC, Rodgers A, Clark T, Gray H, Reid IR, Dunn L, et al. A systematic survey of 13 trials of nonsteroidal anti-inflammatory drugs for the prevention of heterotopic bone formation after major hip surgery. Acta Orthop Scand 2000;71:122-8.
73. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001;120:594-606.
74. Case DL, Kimmick G, Paskett ED, Lohman K, Tucker R. Interpreting measures of treatment effect in cancer clinical trials. Oncologist 2002;7:181-7.
75. Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, van der Meulen JH, et al. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 1999;282:1061-6.
76. Colditz GA, Miller JN, Mosteller F. How study design affects outcomes in comparisons of therapy. Stat Med 1989;8:441-54.
77. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer in elderly persons. Ann Intern Med 1991;114:257-63.
78. Bombardier C, Laine L, Reicin A, Shapira D, Burgos-Vargas R, Davis B, et al. Comparison of upper intestinal toxicity of rafecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
79. Lanza FL. A review of gastric ulcer and gastroduodenal injury in normal volunteers receiving aspirin and other non-steroidal anti-inflammatory drugs. Scand J Gastroenterol 1989;24(suppl 163):24-31.
80. Katz N. Coxibs: evolving role in pain management. Semin Arthritis Rheum 2003;32(suppl):15-24.
81. Rahme E, Joseph L, Kong SX, Watson DJ, Pellissier JM, LeLorier J. Gastrointestinal-related healthcare resource usage associated with a fixed combination of diclofenac and misoprostol versus other NSAIDs. Pharmacoeconomics 2001;19:577-88.
82. Medina Santillan R, Reyes Garcia G, Mateos Garcia E. Prevention of gastroduodenal injury induced by NSAIDs with low-dose misoprostol. Proc West Pharmacol Soc 1999;42:33-4.
83. Nelson R. Coxibs not cost-effective for arthritis in most patients. Lancet 2003;361:1796.
84. Laine L. Coxibs were not cost-effective for arthritis pain in patients with average risk for ulcer complications. ACP Journal Club 2003;139:53.